Payment overview · 2025
General Payments
$727.34
52 reported records · 13 companies
Healthcare provider profile · identity verified
Casey Long, M.D.
Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine · MONTGOMERY, AL · NPI 1609284751
Verified facts
What the public records show
CMS Open Payments records show Casey Long, M.D. received $727.34 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $189.90 | 26.1% | 19 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $139.25 | 19.1% | 12 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $89.20 | 12.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.37 | 10.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.55 | 8.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.57 | 5.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.62 | 3.8% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $23.38 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.73 | 3.0% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $17.12 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.95 | 2.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.95 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.75 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.34 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.04 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $110.33 | 8 | 2025 |
Source payment records
|
|||||
| Infinion 16 Normalized: infinion 16 |
Device | Boston Scientific Corporation | $108.80 | 9 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $89.20 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.33 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.43 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.57 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.83 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $22.50 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $18.12 | 2 | 2025 |
Source payment records
|
|||||
| ARROW Normalized: arrow |
Device | Teleflex LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Artisan Normalized: artisan |
Device | Boston Scientific Corporation | $12.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
98 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
162 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1064 | 182 |
| Gabapentin | Gabapentin | 806 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 168 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 437 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 426 | 131 |
| Omeprazole | Omeprazole | 354 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 350 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 106 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 314 | 61 |
| Lisinopril | Lisinopril | 291 | 81 |
| Pregabalin | Pregabalin | 288 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 238 | 59 |
| Metformin Hcl | Metformin Hcl | 236 | 73 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 233 | 48 |
| Trazodone Hcl | Trazodone Hcl | 216 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 197 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 59 |
| Buspirone Hcl | Buspirone Hcl | 186 | 41 |
| Losartan Potassium | Losartan Potassium | 184 | 60 |
| Montelukast Sodium | Montelukast Sodium | 182 | 53 |
| Celecoxib | Celecoxib | 173 | 50 |
| Mounjaro | Tirzepatide | 162 | 39 |
| Potassium Chloride | Potassium Chloride | 160 | 58 |
| Furosemide | Furosemide | 157 | 54 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 151 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 20 |
| Carvedilol | Carvedilol | 140 | 41 |
| Tramadol Hcl | Tramadol Hcl | 139 | 31 |
| Meloxicam | Meloxicam | 137 | 37 |
| Jardiance | Empagliflozin | 134 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 40 |
| Ozempic | Semaglutide | 123 | 28 |
| Famotidine | Famotidine | 118 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 26 |
| Ibuprofen | Ibuprofen | 112 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 27 |
| Linzess | Linaclotide | 98 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 29 |
| Simvastatin | Simvastatin | 97 | 28 |
| Clonidine Hcl | Clonidine Hcl | 96 | 43 |
| Ondansetron Odt | Ondansetron | 96 | 40 |
| Methocarbamol | Methocarbamol | 92 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 77 | 26 |
| Clonazepam | Clonazepam | 76 | 15 |
| Farxiga | Dapagliflozin Propanediol | 76 | 18 |
| Ezetimibe | Ezetimibe | 73 | 24 |
| Sertraline Hcl | Sertraline Hcl | 71 | 22 |
| Fenofibrate | Fenofibrate | 70 | 15 |
| Baclofen | Baclofen | 69 | 13 |
| Eliquis | Apixaban | 69 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 66 | 13 |
| Topiramate | Topiramate | 63 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 18 |
| Alendronate Sodium | Alendronate Sodium | 57 | 12 |
| Chlorthalidone | Chlorthalidone | 57 | 14 |
| Spironolactone | Spironolactone | 54 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 14 |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Estradiol | Estradiol | 53 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 12 |
| Glipizide | Glipizide | 48 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 24 |
| Allopurinol | Allopurinol | 45 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 13 |
| Sucralfate | Sucralfate | 43 | 12 |
| Levetiracetam | Levetiracetam | 42 | 11 |
| Lidocaine | Lidocaine | 42 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 12 |
| Valsartan | Valsartan | 42 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Levofloxacin | Levofloxacin | 40 | 37 |
| Prednisone | Prednisone | 40 | 33 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | 15 |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 12 |
| Azithromycin | Azithromycin | 34 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 12 |
| Gemtesa | Vibegron | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 14 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Buprenorphine | Buprenorphine | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.34 · 52 records | ABBVIE INC. | AIRSUPRA, ARROW, Artisan, BREZTRI, BRIXADI, Cologuard Collection Kit, FANAPT, FARXIGA, General - Therapies, Infinion 16, JARDIANCE, Kerendia, MAVYRET, QULIPTA, REXULTI, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VERQUVO, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error